Company profile

Sorrento Therapeutics, Inc.

Privately held: no public share price (Formerly Nasdaq-listed (SRNE); delisted effective 2023-04-24 following its Feb 2023 Chapter 11 filing (SEC Form 25-NSE, marketscreener). Briefly emerged from bankruptcy April 2024 but its court-approved liquidation plan (confirmed 2026-07-24) confirms a total loss for equity holders, with the stock trading at $0.00 -- no longer a going public concern; marked private/defunct rather than public. Sources: https://clinicaltrials.gov/study/NCT03464916 Entity resolved by asset-pipeline-v2.)

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
STI-6129
Phase 2
CD38Antibody–drug conjugate
Multiple Myeloma

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.